Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Clinical Diagnostics Insider
(formerly Diagnostic Testing and Emerging Technologies)
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
A Closer Lab-Patient Connection
Patient access to data from the clinical lab is increasing. What does this mean for those generating it?
New and Improved: The Latest Research in Disease Screening
New ideas and innovations look beyond conventional screening options to facilitate improved disease diagnosis and patient outcomes
POC Susceptibility Testing No Aid for Antibiotic Prescribing with UTI
From - Diagnostic Testing & Emerging Technologies
Adding point-of-care (POC) susceptibility testing to POC culture does not improve appropriateness of antibiotic prescribing for patients with suspected…
Teaching Hospitals Consistently Order More Lab Tests Per Patient
From - Diagnostic Testing & Emerging Technologies
A new study validates the long-held assumption that intensity of care is consistently higher at teaching hospitals, compared to nonteaching hospitals. Patients in Texas admitted to…
FDA Warns About Biotin Interference With Lab Tests
...
Already a member? Log in here
Pediatric Offices Fail to Act on 1 in 10 Abnormal Test Results
...
Already a member? Log in here
Foster Kids’ Standard Screenings Tests May Be of Low Value
...
Already a member? Log in here
AMP Issues Consensus Guidelines for NGS Bioinformatics Pipelines
...
Already a member? Log in here
FDA Continues Easing DTC, Home Use Test Regulations
From - Diagnostic Testing & Emerging Technologies
In a continued reversal of its 2013 crackdown on direct-to-consumer (DTC) genetic tests, the U.S. Food and Drug Administration (FDA) unveiled…
Novel Tests Emerging For Overlooked Conditions
From - Diagnostic Testing & Emerging Technologies
Undeniably, much of the emerging test focus is on cancer and infectious diseases. DTET wants to showcase other novel tests entering the marketplace. What follows is…